Viking Therapeutics (1VT) Stock Forecast & Price Target
76 Followers
1VT Analyst Ratings
Strong Buy
17Buy1Hold0Sell
Based on 18 analysts giving stock ratings to Viking Therapeutics in the past 3 months
1VT Stock 12 Month Forecast
Average Price Target
EUR 83.54▲(248.06% Upside)Based on 18 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is EUR 83.54 with a high forecast of EUR 111.92 and a low forecast of EUR 30.44. The average price target represents a 248.06% change from the last price of EUR 24.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 111.92
AverageEUR 83.54
LowEUR 30.44
Highest Price TargetHighestEUR 111.92Average Price TargetEUR 83.54Lowest Price TargetLowestEUR 30.44
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Edward Nash | Canaccord Genuity | EUR 94.91→EUR 105.66 | buy | 340.24%Upside | Reiterated | 10/30/26 | ||
| Naz Rahman | Maxim Group | EUR 62.68 | buy | 161.16%Upside | Reiterated | 10/30/26 | ||
| Joseph Pantginis | H.C. Wainwright | EUR 80.59→EUR 91.33 | buy | 280.54%Upside | Reiterated | 10/29/26 | ||
| Biren Amin | Piper Sandler | EUR 80.59 | buy | 235.77%Upside | Assigned | 10/29/26 | ||
| Joon Lee | UBS | EUR 84.17 | buy | 250.70%Upside | Reiterated | 10/29/26 | ||
| Jeet Mukherjee | BTIG | EUR 111.92 | buy | 366.35%Upside | Reiterated | 10/29/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | EUR 105.66 | buy | 340.24%Upside | Reiterated | 10/29/26 | ||
| Annabel Samimy | Stifel Nicolaus | EUR 85.06 | buy | 254.43%Upside | Reiterated | 10/29/26 | ||
| Jay Olson | Oppenheimer | EUR 107.45 | buy | 347.70%Upside | Reiterated | 10/29/26 | ||
| Michael Ulz | Morgan Stanley | EUR 85.06 | buy | 254.43%Upside | Assigned | 10/29/26 | ||
| William Wood | B. Riley Securities | EUR 76.11 | buy | 217.12%Upside | Reiterated | 10/29/26 | ||
| Richard Law CFA | Goldman Sachs | EUR 34.03→EUR 30.44 | hold | 26.85%Upside | Assigned | 10/28/26 | ||
| Steven Seedhouse | Cantor Fitzgerald | EUR 89.54 | buy | 273.08%Upside | Reiterated | 10/28/26 | ||
| Gregory Renza | Truist Financial | EUR 77.90→EUR 76.11 | buy | 217.12%Upside | Reiterated | 10/07/26 | ||
| Daniel Brims | Lake Street | EUR 79.69 | buy | 232.04%Upside | Reiterated | 09/23/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Edward NashCanaccord Genuity | BuyReiteratedEUR 94.91→EUR 105.66 | 10/30/26 | 340.24%Upside | ||
| Naz RahmanMaxim Group | BuyReiteratedEUR 62.68 | 10/30/26 | 161.16%Upside | ||
| Joseph PantginisH.C. Wainwright | BuyReiteratedEUR 80.59→EUR 91.33 | 10/29/26 | 280.54%Upside | ||
| Biren AminPiper Sandler | BuyAssignedEUR 80.59 | 10/29/26 | 235.77%Upside | ||
| Joon LeeUBS | BuyReiteratedEUR 84.17 | 10/29/26 | 250.70%Upside | ||
| Jeet MukherjeeBTIG | BuyReiteratedEUR 111.92 | 10/29/26 | 366.35%Upside | ||
| Unknown AnalystLeerink PartnersNot Ranked | BuyReiteratedEUR 105.66 | 10/29/26 | 340.24%Upside | ||
| Annabel SamimyStifel Nicolaus | BuyReiteratedEUR 85.06 | 10/29/26 | 254.43%Upside | ||
| Jay OlsonOppenheimer | BuyReiteratedEUR 107.45 | 10/29/26 | 347.70%Upside | ||
| Michael UlzMorgan Stanley | BuyAssignedEUR 85.06 | 10/29/26 | 254.43%Upside | ||
| William WoodB. Riley Securities | BuyReiteratedEUR 76.11 | 10/29/26 | 217.12%Upside | ||
| Richard Law CFAGoldman Sachs | HoldAssignedEUR 34.03→EUR 30.44 | 10/28/26 | 26.85%Upside | ||
| Steven SeedhouseCantor Fitzgerald | BuyReiteratedEUR 89.54 | 10/28/26 | 273.08%Upside | ||
| Gregory RenzaTruist Financial | BuyReiteratedEUR 77.90→EUR 76.11 | 10/07/26 | 217.12%Upside | ||
| Daniel BrimsLake Street | BuyReiteratedEUR 79.69 | 09/23/26 | 232.04%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Viking Therapeutics
3 Months
Success Rate14/24 ratings generated profit
58%
Average Return
+31.00%
Copying Jay Olson's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +31.00% per trade.
1 Year
Success Rate13/24 ratings generated profit
54%
Average Return
+81.75%
Copying Jay Olson's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +81.75% per trade.
2 Years
Success Rate11/24 ratings generated profit
46%
Average Return
+75.08%
Copying Jay Olson's trades and holding each position for 2 Years would result in 45.83% of your transactions generating a profit, with an average return of +75.08% per trade.
1VT Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 23 | 21 | 29 | 37 | 34 |
| Buy | 5 | 5 | 3 | 1 | 1 |
| Hold | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 28 | 26 | 33 | 40 | 37 |
In the current month, 1VT has received 35 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 1VT average Analyst price target in the past 3 months is 83.54.
1VT Financial Forecast
HighEUR -0.90
ConsensusEUR -1.22
LowEUR -1.44
1VT Earnings Forecast
Next quarter’s earnings estimate for 1VT is -EUR 1.22 with a range of -EUR 1.44 to -EUR 0.90. The previous quarter’s EPS was -EUR 1.38. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 0.00
ConsensusEUR 0.00
LowEUR 0.00
1VT Sales Forecast
Next quarter’s sales forecast for 1VT is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1VT Stock Forecast FAQ
What is DE:1VT’s average 12-month price target, according to analysts?
Based on analyst ratings, Viking Therapeutics’s 12-month average price target is €83.54.
What is DE:1VT’s upside potential, based on the analysts’ average price target?
Viking Therapeutics has 248.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Viking Therapeutics a Buy, Sell or Hold?
Viking Therapeutics has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
What is Viking Therapeutics’s share price target?
The average share price target for Viking Therapeutics is €83.54. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €111.92, and the lowest forecast is €30.44. The average share price target represents a 248.06% increase from the current price of €24.
What do analysts say about Viking Therapeutics?
Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of Viking Therapeutics?
To buy shares of DE:1VT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
